NASDAQ:ATRSAntares Pharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Antares Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.72 +0.20 (+7.94 %) (As of 04/9/2020 04:00 PM ET) Add Compare Share Today's Range$2.55Now: $2.72▼$2.7550-Day Range$1.75MA: $2.69▼$3.5352-Week Range$1.60Now: $2.72▼$5.13Volume1.69 million shsAverage Volume1.67 million shsMarket Capitalization$450.32 millionP/E RatioN/ADividend YieldN/ABeta1.18 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., and Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.Read More Beat the Market (BTM) Rank™ 3.8 Analyst's Opinion Consensus RatingAntares Pharma has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.50, Antares Pharma has a potential upside of 102.2% from its current price of $2.72.Amount of Analyst CoverageAntares Pharma has only been the subject of 2 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesAntares Pharma has received 382 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAntares Pharma has received 302 “underperform” votes. (Add your “underperform” vote.)Community SentimentAntares Pharma has received 55.85% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote “Outperform” if you believe ATRS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ATRS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAntares Pharma does not currently pay a dividend.Dividend GrowthAntares Pharma does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Antares Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $252.00 in company stock.Percentage Held by InsidersOnly 5.49% of the stock of Antares Pharma is held by insiders.Percentage Held by Institutions40.13% of the stock of Antares Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Antares Pharma are expected to grow by 287.50% in the coming year, from $0.08 to $0.31 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Antares Pharma is -272.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Antares Pharma is -272.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAntares Pharma has a P/B Ratio of 8.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.8Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.89 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:ATRS Previous Symbol CUSIP03664210 CIK1016169 Webhttp://www.antarespharma.com/ Phone609-359-3020Debt Debt-to-Equity Ratio0.74 Current Ratio3.35 Quick Ratio2.85Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio34.00 P/E GrowthN/A Sales & Book Value Annual Sales$123.86 million Price / Sales3.64 Cash Flow$0.00 per share Price / Cash Flow732.98 Book Value$0.33 per share Price / Book8.24Profitability EPS (Most Recent Fiscal Year)($0.01) Net Income$-2,030,000.00 Net Margins-1.64% Return on Equity-4.43% Return on Assets-1.75%Miscellaneous Employees165 Outstanding Shares165,560,000Market Cap$450.32 million Next Earnings Date5/7/2020 (Estimated) OptionableOptionable Receive ATRS News and Ratings via Email Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ATRS Rates by TradingView Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions How has Antares Pharma's stock been impacted by COVID-19 (Coronavirus)? Antares Pharma's stock was trading at $3.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ATRS shares have decreased by 9.3% and is now trading at $2.72. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Antares Pharma? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 1 buy rating and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Strong Buy." View analyst ratings for Antares Pharma. When is Antares Pharma's next earnings date? Antares Pharma is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Antares Pharma. How were Antares Pharma's earnings last quarter? Antares Pharma Inc (NASDAQ:ATRS) posted its quarterly earnings data on Tuesday, March, 3rd. The specialty pharmaceutical company reported $0.03 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.00 by $0.03. The specialty pharmaceutical company had revenue of $37.84 million for the quarter, compared to analyst estimates of $34.35 million. Antares Pharma had a negative return on equity of 4.43% and a negative net margin of 1.64%. View Antares Pharma's earnings history. What guidance has Antares Pharma issued on next quarter's earnings? Antares Pharma updated its FY 2020 Pre-Market earnings guidance on Tuesday, March, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $135-155 million, compared to the consensus revenue estimate of $147.56 million. What price target have analysts set for ATRS? 2 analysts have issued 1 year target prices for Antares Pharma's shares. Their forecasts range from $5.00 to $6.00. On average, they expect Antares Pharma's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 102.2% from the stock's current price. View analysts' price targets for Antares Pharma. Has Antares Pharma been receiving favorable news coverage? Headlines about ATRS stock have trended very negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Antares Pharma earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutAntares Pharma. Are investors shorting Antares Pharma? Antares Pharma saw a drop in short interest in March. As of March 13th, there was short interest totaling 4,735,600 shares, a drop of 24.2% from the February 27th total of 6,250,000 shares. Based on an average trading volume of 2,144,500 shares, the days-to-cover ratio is currently 2.2 days. Approximately 3.1% of the shares of the stock are short sold. View Antares Pharma's Current Options Chain. Who are some of Antares Pharma's key competitors? Some companies that are related to Antares Pharma include Cooper Companies (COO), Align Technology (ALGN), West Pharmaceutical Services (WST), DENTSPLY SIRONA (XRAY), Haemonetics (HAE), ICU Medical (ICUI), Quidel (QDEL), Neogen (NEOG), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Cerus (CERS), OraSure Technologies (OSUR), Anika Therapeutics (ANIK) and Meridian Bioscience (VIVO). What other stocks do shareholders of Antares Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Antares Pharma investors own include Ballard Power Systems (BLDP), Novavax (NVAX), Conatus Pharmaceuticals (CNAT), NVIDIA (NVDA), Advanced Micro Devices (AMD), Prospect Capital (PSEC), Hi-Crush Partners (HCLP), Macquarie Infrastructure (MIC), Amarin (AMRN) and AT&T (T). Who are Antares Pharma's key executives? Antares Pharma's management team includes the following people: Mr. Robert F. Apple, CEO, Pres & Director (Age 53)Mr. Fred M. Powell, Exec. VP & CFO (Age 58)Mr. Peter J. Graham, Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 52)Dr. James Patrick Tursi, EVP, Head of R&D & Chief Medical Officer (Age 54)Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 56) What is Antares Pharma's stock symbol? Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS." How do I buy shares of Antares Pharma? Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Antares Pharma's stock price today? One share of ATRS stock can currently be purchased for approximately $2.72. How big of a company is Antares Pharma? Antares Pharma has a market capitalization of $450.32 million and generates $123.86 million in revenue each year. The specialty pharmaceutical company earns $-2,030,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis. Antares Pharma employs 165 workers across the globe. View additional information about Antares Pharma. What is Antares Pharma's official website? The official website for Antares Pharma is http://www.antarespharma.com/. How can I contact Antares Pharma? Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected] This page was last updated on 4/9/2020 by MarketBeat.com StaffFeatured Article: What is included in the gross domestic product?
